US10307392B2 – June 4, 2019 – Compound and method for treatment of diseases and disorders

Please complete the required fields.




Inventors :

Alexander Kariman

Owner :

Kariman, Alexander

Application Number :

US15789998

Document Number :

US10307392B2

Priority Date :

October 21, 2017

Filing Date :

October 21, 2017

Date of Grant/ Publication :

June 4, 2019

Class :

; A61K31 / 353; A61K31 / 352; A61K36 / 185; A61K31 / 05

Abstract

The disclosed invention generally relates to treatment and/or prevention of symptoms associated with cannabinoid responsive diseases and disorders in subjects in need thereof, as well as the method of administering therapeutically-effective amount of a pharmaceutical compound containing cannabinoids. The disclosed invention further relates to pharmaceutical compounds for treating and/or preventing symptoms associated with said diseases and disorders.

Claim(s)

1. A method of treating with reduced adverse psychotropic effect pain, inflammation, mood and motor symptoms associated with psychiatric, autoimmune and neurological diseases and disorders in a subject manifesting one or more of said symptoms, the method comprising administering to a subject 0.3 mg or more of a pharmaceutical compound one or more times in 24 hours, comprising of an extract of a Cannabis plant and at least one pharmacologically inactive substance; and where said extract contains one or more tetrahydrocannabinol (THC) isomers and one or more cannabidiol (CBD) isomers in the ratio of 1 (THC) and 2 (CBD) by mass; and where said CBD augments the pharmacodynamics of THC in a subject; and where said compound contains one or more non-cannabinoid components consisting of one or more of the following: terpenes; sterols; triglycerides; alkanes; squalene; tocopherol; carotenoids; chlorophyll; flavonoid; glycosides and alkaloids.;
14. A pharmaceutical compound for treating with reduced adverse psychotropic effect pain, inflammation, mood and motor symptoms associated with psychiatric, autoimmune and neurological diseases and disorders in a subject manifesting one or more of said symptoms, comprising of an extract of Cannabis sativa plant and at least one pharmacologically inactive substance; and where said extract contains one or more tetrahydrocannabinol (THC) isomers and one or more cannabidiol (CBD) isomers in the ratio of 1 (THC) and 2 (CBD) by mass; and where said CBD augments the pharmacodynamics of THC in a subject; and where said compound contains one or more non-cannabinoid components consisting of one or more of the following: terpenes; sterols; triglycerides; alkanes; squalene; tocopherol; carotenoids; chlorophyll; flavonoid; glycosides and alkaloids.;
27. A pharmaceutical compound for treating with reduced adverse psychotropic effect pain, inflammation, mood and motor symptoms associated with psychiatric, autoimmune and neurological diseases and disorders in a subject manifesting one or more of said symptoms, comprising of an extract of one or more Cannabis species plants and at least one pharmacologically inactive substance; and where said compound is packaged in a soft gelatin capsule, where said capsule does not contain lambda-carrageenan, kappa-carrageenan, iota-carrageenan and any mixture of the carrageenans.

Summary

No Comments

Leave a comment

Sorry, you must be logged in to post a comment. Login